CONDENSED CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 85,749	$ 80,428
Marketable securities	272,381	282,046
Interest receivable	926	682
Accounts receivable	6,970	36,909
Prepaid expenses and other current assets	4,922	5,408
Total current assets	370,948	405,473
Marketable securities, non-current	5,000	21,832
Property and equipment, net	31,294	29,926
Intangible assets	52,137	53,156
Goodwill	38,550	39,273
Operating lease right-of-use assets	75,377	77,289
Other non-current assets	9,470	9,067
Non-current restricted cash	1,500	1,500
Total assets	584,276	637,516
Current liabilities:
Accounts payable and accrued liabilities	16,923	17,556
Accrued compensation and employee benefits	8,592	13,605
Deferred revenues	36,550	38,711
Total current liabilities	62,065	69,872
Deferred revenues, non-current	75,274	81,432
Long-term portion of lease liabilities	40,198	41,192
Deferred income tax	6,444	6,570
Other non-current liabilities	5,880	5,711
Total liabilities	189,861	204,777
Commitments and contingencies
Stockholders' equity:
Preferred stock	0	0
Common stock	1,163	1,160
Additional paid-in capital	1,096,854	1,090,828
Accumulated deficit	(699,898)	(656,985)
Accumulated other comprehensive loss	(3,828)	(2,449)
Total Sangamo Therapeutics, Inc. stockholders' equity	394,291	432,554
Non-controlling interest	124	185
Total stockholders' equity	394,415	432,739
Total liabilities and stockholders' equity	$ 584,276	$ 637,516